Samsung Bioepis and Pfizer will compete in the domestic market for anti-cancer drug Avastin (Bevacizumab, Roche Korea). There will be a rare competition between domestic companies and global companies over generics.

The MFDS approved Jairabeve of Pfizer Korea on the 18th. Jairabeve (Bevacizumab) is biosimilar for Avastin in Roche, Korea.

Equivalence between Jairabeve and Avastin has been demonstrated. Clinical trials were conducted to assess the equivalence of drug in a total of 388 patients with progressive or metastatic non-small cell lung cancer with healthy adult male volunteers, demonstrating statistical equivalence.

Avastin recorded sales of ₩118 billion in Sou